Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech (ALVO) has finalized a private placement of 7,500,000 shares (Swedish Depository Receipts and ordinary shares) at SEK 100.00/SDR and ISK 1320.83/ordinary share, raising gross proceeds of SEK 750 million. The placement, managed by DNB Carnegie, Citi, SEB, and ACRO, attracted strong interest from Swedish and international institutional investors and will use existing treasury shares. Net proceeds will be used to upscale R&D, capitalize on growth opportunities, and for general corporate purposes.

Analysis

Alvotech has successfully completed a private placement, raising gross proceeds of SEK 750 million by issuing the equivalent of 7.5 million shares, comprising 5,833,500 Swedish Depository Receipts (SDRs) priced at SEK 100.00 each and 1,666,500 ordinary shares (ALVOIS) at an equivalent ISK 1320.83. The placement, executed via an accelerated bookbuilding procedure led by DNB Carnegie and Citi, garnered strong interest from institutional investors, with a significant allocation to Swedish and other international investors, highlighting the strategic importance of Alvotech's SDR listing on Nasdaq Stockholm. The shares for this placement will be sourced from existing treasury shares held by Alvotech. The net proceeds are earmarked for critical growth initiatives: (i) upscaling R&D efforts, particularly in Sweden following the recent acquisition of Xbrane's R&D operations, to further expand its substantial global biosimilars pipeline; (ii) capitalizing on selected growth opportunities to strengthen its market position; and (iii) general corporate purposes. This capital infusion is intended to diversify Alvotech's shareholder base, increase the SDR float, and enable more agile execution of R&D expansion. The transaction is supported by lock-up undertakings from the company, its executive management, board members (180 days), and certain major shareholders (90 days), indicating commitment and aiming to provide share price stability post-placement. The strongly positive sentiment surrounding this announcement (ALVO sentiment: 0.85) reflects market confidence in these strategic moves.

Key Decisions for Investors

• Investors should interpret the strong institutional demand in this SEK 750 million private placement as a positive signal of market confidence in Alvotech's strategic direction and its biosimilar pipeline.
• Monitor Alvotech's execution on its stated use of proceeds, particularly the integration of Xbrane's R&D operations and subsequent advancements in its pipeline, as these will be key drivers for future value creation.
• While the use of treasury shares avoids immediate new share dilution, investors should be cognizant of the lock-up expiration dates (90 and 180 days post-settlement around June 10, 2025) for potential increased trading volume or selling pressure from insiders and major shareholders.